229 related articles for article (PubMed ID: 12174634)
1. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
4. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
Iyer RV; Hanlon AL; Pinover WH; Hanks GE
Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
[TBL] [Abstract][Full Text] [Related]
5. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
6. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
7. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
9. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups.
Stamey TA; Sözen TS; Yemoto CM; McNeal JE
J Urol; 1998 Jun; 159(6):2009-12. PubMed ID: 9598508
[TBL] [Abstract][Full Text] [Related]
10. Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?
Billis A; Meirelles LL; Freitas LL; Magna LA; Reis LO; Ferreira U
Int Urol Nephrol; 2011 Sep; 43(3):707-14. PubMed ID: 21336958
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?
Cagiannos I; Graefen M; Karakiewicz PI; Ohori M; Eastham JA; Rabbani F; Fair W; Wheeler TM; Hammerer PG; Haese A; Erbersdobler A; Huland H; Scardino PT; Kattan MW
J Clin Oncol; 2002 Apr; 20(8):2025-30. PubMed ID: 11956261
[TBL] [Abstract][Full Text] [Related]
12. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma.
Eichelberger LE; Cheng L
Cancer; 2004 Jun; 100(12):2573-6. PubMed ID: 15197798
[TBL] [Abstract][Full Text] [Related]
13. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
[TBL] [Abstract][Full Text] [Related]
14. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.
Liebross RH; Pollack A; Lankford SP; von Eschenbach AC; Zagars GK
Urology; 1998 Oct; 52(4):647-52. PubMed ID: 9763087
[TBL] [Abstract][Full Text] [Related]
15. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
16. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
18. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
19. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
